Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP1 | P03956 | 20/20 | 0.78 |
| ▸ | ADAM17 | P78536 | 15/20 | 0.78 |
| ▸ | MMP13 | P45452 | 15/20 | 0.78 |
| ▸ | MMP3 | P08254 | 7/20 | 0.78 |
| ▸ | MMP9 | P14780 | 7/20 | 0.78 |
| ▸ | MMP2 | P08253 | 6/20 | 0.78 |
| ▸ | MMP7 | P09237 | 5/20 | 0.78 |
| ▸ | MMP8 | P22894 | 3/20 | 0.78 |
| ▸ | MMP14 | P50281 | 2/20 | 0.78 |
| ▸ | ADAM10 | O14672 | 2/20 | 0.68 |
| ▸ | ADAM9 | Q13443 | 2/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6381652 | 1.00 | MMP1 (0.78) | MMP1ADAM17MMP13MMP3MMP9 | |
| SCHEMBL7075595 | 0.91 | MMP1 (0.75) | MMP1ADAM17MMP13MMP3MMP9 | |
| SCHEMBL7055124 | 0.88 | MMP1 (0.73) | MMP1ADAM17MMP13MMP3MMP9 | |
| SCHEMBL8661132 | 0.88 | MMP1 (0.60) | MMP1ADAM17MMP13MMP3MMP9 | |
| SCHEMBL7055128 | 0.88 | MMP1 (0.73) | MMP1ADAM17MMP13MMP3MMP9 | |
| Prinomastat SCHEMBL6801875 | 0.88 | MMP1 (1.00) | MMP1ADAM17MMP13MMP3MMP9 | |
| Prinomastat SCHEMBL3955053 | 0.88 | MMP1 (1.00) | MMP1ADAM17MMP13MMP3MMP9 | |
| Prinomastat SCHEMBL115696 | 0.88 | MMP1 (1.00) | MMP1ADAM17MMP13MMP3MMP9 | |
| SCHEMBL7051193 | 0.88 | MMP1 (0.70) | MMP1ADAM17MMP13MMP3MMP9 | |
| SCHEMBL7051190 | 0.88 | MMP1 (0.70) | MMP1ADAM17MMP13MMP3MMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1098662-A2 | COADMINISTRATION OF ACAT AND MMP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROTIC LESIONS | WARNER-LAMBERT COMPANY (US) | 2001-05-16 | — | — | EP | claimed |
| WO-2000004892-A2 | COADMINISTRATION OF ACAT AND MMP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROTIC LESIONS | WARNER-LAMBERT COMPANY (US) | 2000-02-03 | — | — | WO | claimed |
| EP-1098662-A2 | COADMINISTRATION OF ACAT AND MMP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROTIC LESIONS | WARNER-LAMBERT COMPANY (US) | 2001-05-16 | — | — | EP | disclosed |
| WO-2000004892-A2 | COADMINISTRATION OF ACAT AND MMP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROTIC LESIONS | WARNER-LAMBERT COMPANY (US) | 2000-02-03 | — | — | WO | disclosed |